SEHK:2268Life Sciences
WuXi XDC Cayman (SEHK:2268) Is Down 5.7% After Exclusive WuXiTecan-2 Licensing Deal – Has The Bull Case Changed?
In February 2026, Earendil Labs announced a collaboration with WuXi XDC Cayman Inc., securing an exclusive global license to WuXi XDC’s proprietary WuXiTecan-2 payload-linker platform for multiple targets, alongside up to approximately US$885 million in potential upfront and milestone payments plus tiered royalties.
The partnership combines Earendil’s AI-driven antibody discovery with WuXi XDC’s integrated bioconjugate CRDMO capabilities, positioning WuXi XDC as a key enabler in...